Display options
Cite
Piperno-Neumann S, Piulats JM, Goebeler M, et al. Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers (Basel). 2019;11(6)doi: 10.3390/cancers11060817.
Piperno-Neumann, S., Piulats, J. M., Goebeler, M., Galloway, I., Lugowska, I., Becker, J. C., Vihinen, P., Van Calster, J., Hadjistilianou, T., Proença, R., Caminal, J. M., Rogasik, M., Blay, J. Y., & Kapiteijn, E. (2019). Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers, 11(6), . https://doi.org/10.3390/cancers11060817
Piperno-Neumann, Sophie, et al. "Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer." Cancers vol. 11,6 (2019). doi: https://doi.org/10.3390/cancers11060817
Piperno-Neumann S, Piulats JM, Goebeler M, Galloway I, Lugowska I, Becker JC, Vihinen P, Van Calster J, Hadjistilianou T, Proença R, Caminal JM, Rogasik M, Blay JY, Kapiteijn E. Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers (Basel). 2019 Jun 13;11(6). doi: 10.3390/cancers11060817. PMID: 31200439; PMCID: PMC6628377.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Jun 13;11(6). doi: 10.3390/cancers11060817.

Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer.

Cancers

Sophie Piperno-Neumann, Jose Maria Piulats, Matthias Goebeler, Iain Galloway, Iwona Lugowska, Jürgen C Becker, Pia Vihinen, Joachim Van Calster, Theodora Hadjistilianou, Rui Proença, Jose Maria Caminal, Muriel Rogasik, Jean-Yves Blay, Ellen Kapiteijn

Affiliations

  1. Department of Medical Oncology, Institut Curie, 75005 Paris, France. [email protected].
  2. Department of Medical Oncology, Catalan Cancer Institute, IDIBELL, CIBERONC, Hospitalet de Llobregat, 08908 Barcelona, Spain. [email protected].
  3. Department of Dermatology, University Hospital Würzburg, 97080 Würzburg, Germany. [email protected].
  4. European Patient Advocacy Group: Melanoma Patient Network Europe & OcuMel, Birmingham B13 8ET, UK. [email protected].
  5. Department of Melanoma, Maria Sk?odowska Curie Institute-Oncology Centre, 02-034 Warsaw, Poland. [email protected].
  6. Translational Skin Cancer Research, University of Essen-Duisburg, German Cancer Consortium (DKTK), 47057 Duisburg, Germany. [email protected].
  7. Department of Oncology and FICAN West Cancer Center, Turku University Hospital, 20521 Turku, Finland. [email protected].
  8. Department of Ophthalmology, UZ Leuven, 3000 Leuven, Belgium. [email protected].
  9. Department of Ophthalmology, Università degli Studi di Siena UNISI, 53100 Siena, Italy. [email protected].
  10. Onco-Ophthalmology National Reference Centre, CHUC, 3075 Coimbra, Portugal. [email protected].
  11. Department of Ophthalmololgy, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. [email protected].
  12. EURACAn coordination team, Centre Léon Bérard, 69008 Lyon, France. [email protected].
  13. EURACAN network coordinator, Department of Medical Oncology, Centre Léon Bérard, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France. [email protected].
  14. Department of Medical Oncology, LUMC, 2333 ZA Leiden, the Netherlands. [email protected].

PMID: 31200439 PMCID: PMC6628377 DOI: 10.3390/cancers11060817

Abstract

Uveal melanoma (UM) is the most frequent primary ocular cancer in adults, accounting for 5% of all melanomas. Despite effective treatments for the primary tumour, up to 50% of UM patients will develop metastasis, leading to a very poor prognosis and a median overall survival of 6 to 12 months, with no major improvements in the last 30 years. There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM). Recent advances in biology, however, identified specific gene and chromosome alterations, potentially permitting an actively tailored surveillance strategy, and dedicated clinical studies. Being a rare cancer, UM patients have to overcome issues such as identifying referral centres, having access to information, and partnering with oncologists for specific management strategies and research priorities. Here, we describe how the EUropean Rare Adult solid CAacer Network (EURACAN) will help in addressing these challenges and accelerating international collaborations to enhance the development of innovative treatments in UM.

Keywords: European Reference Network; rare cancer; uveal melanoma

References

  1. Cancer Res. 2004 Oct 15;64(20):7205-9 - PubMed
  2. Nature. 2009 Jan 29;457(7229):599-602 - PubMed
  3. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80 - PubMed
  4. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3048-55 - PubMed
  5. Eur J Surg Oncol. 2009 Nov;35(11):1192-7 - PubMed
  6. Science. 2010 Dec 3;330(6009):1410-3 - PubMed
  7. N Engl J Med. 2010 Dec 2;363(23):2191-9 - PubMed
  8. Clin Cancer Res. 2011 Apr 15;17(8):2087-100 - PubMed
  9. Ophthalmology. 2011 Sep;118(9):1881-5 - PubMed
  10. Ophthalmology. 2012 Aug;119(8):1596-603 - PubMed
  11. Front Immunol. 2012 Jun 13;3:148 - PubMed
  12. Lancet Oncol. 2012 Aug;13(8):782-9 - PubMed
  13. Br J Ophthalmol. 2013 Feb;97(2):159-63 - PubMed
  14. Mol Oncol. 2013 Jun;7(3):625-36 - PubMed
  15. JAMA Ophthalmol. 2013 Aug;131(8):993-1003 - PubMed
  16. Br J Ophthalmol. 2014 Jun;98(6):769-74 - PubMed
  17. Cancer Med. 2013 Oct;2(5):674-86 - PubMed
  18. Ann Oncol. 2014 Mar;25(3):742-6 - PubMed
  19. Cancer Cell. 2014 Jun 16;25(6):831-45 - PubMed
  20. JAMA. 2014 Jun 18;311(23):2397-405 - PubMed
  21. Exp Eye Res. 2014 Oct;127:59-68 - PubMed
  22. JAMA Ophthalmol. 2015 Apr;133(4):376-83 - PubMed
  23. J Fr Ophtalmol. 2015 Jun;38(6):526-34 - PubMed
  24. Eur J Cancer. 2015 Nov;51(16):2404-12 - PubMed
  25. Ophthalmology. 2016 Jan;123(1):86-91 - PubMed
  26. Ann Surg Oncol. 2016 Apr;23(4):1309-19 - PubMed
  27. Oncotarget. 2016 Jan 26;7(4):4624-31 - PubMed
  28. Clin Cancer Res. 2016 May 1;22(9):2237-49 - PubMed
  29. Nat Genet. 2016 Jun;48(6):675-80 - PubMed
  30. Lancet Oncol. 2017 Jun;18(6):792-802 - PubMed
  31. Cancer Cell. 2017 Aug 14;32(2):204-220.e15 - PubMed
  32. J Surg Oncol. 2018 May;117(6):1170-1178 - PubMed
  33. Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175 - PubMed
  34. J Clin Oncol. 2018 Apr 20;36(12):1232-1239 - PubMed
  35. Cancer. 2018 Jul 1;124(13):2693-2703 - PubMed
  36. Nat Commun. 2018 May 14;9(1):1866 - PubMed
  37. J Curr Ophthalmol. 2018 Mar 22;30(2):102-109 - PubMed
  38. Immunogenetics. 2019 May;71(5-6):433-436 - PubMed
  39. Cancer Cell. 2019 Mar 18;35(3):457-472.e5 - PubMed
  40. BMC Cancer. 2019 May 2;19(1):415 - PubMed
  41. Ann Oncol. 2019 May 31;:null - PubMed
  42. Lancet. 1996 May 4;347(9010):1222-5 - PubMed

Publication Types